WEBINAR RECORDING AVAILABLE - WATCH ON DEMAND

CDMOs’ critical role in a rapidly evolving biopharma landscape

It is an incredibly dynamic time for CDMOs. With increased awareness of the sector and its growing importance in the pharmaceutical supply chain, CDMOs have become broadly acknowledged as a critical part of the solution for meeting industry challenges, including accessing technologies and capacity, addressing regulatory complexity, and managing fixed costs and investments. Tune in to hear Catalent President and CEO Alessandro Maselli discuss these topics with Endpoints News founder John Carroll and the evolving role of CDMOs, and also touch on what’s next for Catalent, as it progresses with its shift from public to private ownership under its previously announced transaction with Novo Holdings.

watch now

Alessandro Maselli

President & CEO, Catalent

Alessandro Maselli was appointed Catalent’s President and Chief Executive Officer and joined the Board of Directors in July 2022. He previously served as the company’s President & Chief Operating Officer since February 2019. Mr. Maselli joined Catalent in 2010 as Director of Operations at Catalent’s pharmaceutical, nutritional and cosmetics plant in Aprilia, Italy. In 2013, he was appointed General Manager of Zydis® operations at Catalent’s facility in Swindon, U.K, in 2015 he became Vice President of Operations, Europe, for Catalent’s Drug Delivery Solutions business unit, and in 2016 he was named Catalent’s Senior Vice President, Global Operations.

Prior to Catalent, Mr. Maselli held operational and business leadership roles at Alstom and SGS. From 1998 to 2006, he held roles of increasing responsibility from process engineer to operations director at ABB. Mr. Maselli began his career as an automation systems engineer in the food industry.

A native of Italy, Mr. Maselli earned bachelor’s and master’s degrees in electronic engineering from the University of Rome.

moderator

John Carroll

Editor & founder, Endpoints News

John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Aside from his daily industry coverage for FierceBiotech, where he was named editor in 2003, leaving in 2016, Carroll has been a regular speaker at biotech events around the globe. He’s been quoted by The New York Times, The New Yorker, Financial Times, The Times of London and more. He’s also keynoted at biotech gatherings around the world and addressed student audiences at MIT and Harvard. Carroll has contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press. He spent 6 years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times.